Company
Headquarters: The Woodlands, TX, United States
Founded: The Woodlands, TX, 1995
Employees: 87
CEO: Mr. Lonnel Coats
$359.9 Million
USD as of Jan. 1, 2024
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $461.52 B |
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Top 1-year algo backtest: +313.24%
$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Lexicon Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: LXRX wb_incandescent
Stock: FSX: LX31 wb_incandescent
Lonnel Coats, president and chief executive officer Brian P. Zambrowicz, E VP & Chief Scientific Officer Jeffrey L. Wade, E VP of Corporate Development & Chief Scientific Officer Alan J. Main, E VP of Pharmaceutical Research Pablo Lapuerta, E VP of Clinical Development & Chief Medical Officer James F. Tessmer, VP of Finance and Accounting
Revenue: $324.1 Million(2019)